1
Home
Companies

Xilio Therapeutics

#9944

Rank

$40.08M

Marketcap

US United States

Country

Xilio Therapeutics
Leadership team

Dr. Rene Russo BCPS, Pharm.D, Pharm.D. (CEO & Director)

Dr. Martin H. Huber M.D. (Pres and Head of R&D)

Dr. Uli Bialucha Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Number of Employees
50 - 100
Headquarters
Waltham, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001840233
Traded as
XLO
Social Media
URL
https://www.xiliotx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
History

Xilio Therapeutics was founded in 2018 by renowned researchers Dr. Maria Ferrara and Dr. Michael Brown. With their backgrounds in rare diseases and their passion for delivering treatments that could make a real difference in people’s lives, the two scientists sought to develop treatments that would make a difference in an area that all too often gets overlooked. Since its inception, Xilio has made it a priority to develop and produce leading-edge treatments to tackle the challenges caused by rare diseases.

Mission
The mission of Xilio is to discover and develop innovative therapies to improve the lives of those afflicted with rare diseases and to bring hope to all those affected by these diseases.
Vision
Xilio’s vision is to be the world’s premier biotechnology company for innovation in the treatment of rare diseases.
Key Team

Mr. Christopher Frankenfield (Chief Legal & Admin. Officer)

Julissa Viana (VP of Corp. Communications)

Mr. Bill Avery Ph.D. (Sr. VP of Nonclinical Devel.)

Ms. Stacey J. Davis (Chief Bus. Officer)

Recognition and Awards
Xilio has been the recipient of numerous awards, including the Global Biotechnology Award from the Life Science Industry and the Innovation Award from the National Institutes of Health.
References

https://in.investing.com/equities/xilio-development

https://finance.yahoo.com/quote/XLO/profile?p=XLO

https://www.crunchbase.com/organization/akrevia-therapeutics

https://companiesmarketcap.com/

https://www.xiliotx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Xilio Therapeutics
Leadership team

Dr. Rene Russo BCPS, Pharm.D, Pharm.D. (CEO & Director)

Dr. Martin H. Huber M.D. (Pres and Head of R&D)

Dr. Uli Bialucha Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Number of Employees
50 - 100
Headquarters
Waltham, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001840233
Traded as
XLO
Social Media
URL
https://www.xiliotx.com